---
title: Bacteremia and infective endocarditis
creation date: 2024-08-09 16:07
status: finished
tags:
  - teaching
  - medicine/IE
share_link: https://share.note.sx/5kvwmniy#vnlaMyGYciUZN7WsQcuAJmqAA2V3JjfuLe/8d8U8bdw
share_updated: 2024-08-14T17:41:28+08:00
share: true
category: medicine
alias: bacteremia-ie
---
source: Pocket Medicine, 2022  
# 菌血症  
  
## 定義  
  
- 原發性菌血症：由於病原菌直接接種血液而引起的血流感染  
- 中心靜脈導管相關血流感染（CLABSI）：周邊和導管培養中生長出相同菌株的菌血症（CID 2009;49:1）  
- 繼發性菌血症：其他部位的感染（例如，尿路感染、肺炎、結腸炎等）擴散至血液  
- 污染：血液培養中生長的細菌，但不代表真實感染  
  
## 血流感染的風險因子 (JAMA 2012;308:502; CID;2020;71)  
  
- 高菌血症可能性的感染症：  
	- 敗血症  
	- 血管內感染：心內膜炎、節律器感染、血管植入物或靜脈導管感染  
	- 脊椎骨髓炎、硬膜外膿瘍、感染性關節炎  
- 風險因子：留置導管、靜脈注射毒品使用（IVDU）、免疫抑制（嗜中性球減少、移植）  
- 致病微生物：  
	- 更可能為致病菌：*S. aureus*、β-溶血性鏈球菌、腸球菌、革蘭氏陰性桿菌、*S. pneumo*、*Neisseria*、*Candida*  
	- 不太可能為致病菌：coagulase-negative Staphylococcus、白喉桿菌、Cutibacterium  
- 生長時間：<24 小時→風險更高，>72 小時→風險較低（除了生長較慢的，例如 HACEK）  
- 增加心內膜炎可能性的因素：無明顯感染源的高風險菌血症、在移除導管或引流感染源後持續存在菌血症、宿主有心內膜炎風險的中、已知會引起感染性心內膜炎（IE）的微生物、栓塞  
  
## 診斷  
  
- 抗生素治療前應進行至少兩組血液培養（每組包括有氧和厭氧培養），並從不同的穿刺點取樣  
- 如果證實為菌血症，則需每日監測培養，直到**48 小時內培養結果為陰性**。革蘭氏陰性桿菌可能不需要（ClD 2017;65:1776）  
- 如懷疑心內膜炎，需進行經胸前心臟超音波（TTE）/經食道心臟超音波（TEE）（見感染性心內膜炎部分）  
- 如果血液培養中有酵母菌生長，需進行**TTE**和**緊急眼科評估**  
  
## 治療 (CID 2009;49:1; JAMA 2020;323:2160)  
  
- 根據革蘭氏染色、培養結果和臨床症狀選擇經驗性抗生素，然後根據敏感性調整治療方案  
  
### 短期中心靜脈導管相關血流感染  
  
| 病原體                | 治療方案                                                                                                                                                                                                                                          |  
| ------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| **_S. aureus_**    | 菌血症中心內膜炎的風險：約 25%（_JACC_ 1997;30:1072）<br><br>進行感染科會診與降低死亡率相關（_ClD_ 2015;60:1451）<br><br>移除中心靜脈導管（CVC），評估心內膜炎、骨髓炎、植入物感染<br><br>首選抗生素：MSSA→ nafcillin、oxacillin 或 cefazolin。MRSA→ vancomycin。療程：若宿主正常、無植入物、無心內膜炎或轉移性併發症的證據，則療程為 2 週。否則為 4-6 週。 |  
| **CoNS**           | 保留 CVC 並不會降低治癒率，但會增加復發率（_CID_ 2009;49:1187）。如果保留 CVC，治療 10-14 天；如果移除，則治療 5-7 天。                                                                                                                                                               |  
| **_Enterococcus_** | 移除 CVC 並治療 7-14 天                                                                                                                                                                                                                             |  
| **GNB**            | 特別是如果涉及*Pseudomonas aeruginosa*，應移除 CVC。療程為 14 天（如果無併發症，則為 7 天）。                                                                                                                                                                              |  
| **酵母菌**            | 移除 CVC 並治療 14 天，從第一次血液培養陰性開始計算。進行感染科會診與降低死亡率相關。                                                                                                                                                                                               |  
- 持續血液培養陽性：移除 CVC，尋找轉移性感染（心內膜炎、感染性關節炎、骨髓炎）、感染性血栓或人工植入物（血管植入物、節律器）  
  
# 細菌性心內膜炎  
  
## 定義  
  
- 心臟內皮（包括但不限於瓣膜）的感染，包括人工瓣膜心內膜炎（PVE）和天然瓣膜心內膜炎（NVE）  
  
## 危險因子  
- 異常瓣膜（JAMA 1997;277:1794; JACC 2018;72:2443）  
	- 高風險：過去曾有心內膜炎、人工瓣膜或環、某些先天性心臟病（未修復的發紺型；分流/導管；過去 6 個月內植入的人工瓣膜）、移植心臟、瓣膜病、心室輔助幫浦（VAD）  
	- 中等風險：既往風濕熱、非風濕性瓣膜病（包括伴有二尖瓣返流或瓣葉增厚的二尖瓣脫垂）、肥厚型心肌病變、二葉主動脈瓣  
- 菌血症風險：IVDU（靜脈注射毒品使用者）、留置靜脈導管、透析、心臟內植入物（如節律器、心臟整流去顫器、植入物）、口腔衛生差  
  
## 心內膜炎的微生物學  
  
|                  | **天然瓣膜心內膜炎（NVE）** |          | **人工瓣膜心內膜炎（PVE）** |               |  
| ---------------- | ----------------- | -------- | ----------------- | ------------- |  
| **病因**           | **非靜脈注射藥物使用者**    | **IVDU** | **早期**（≤60 天）     | **晚期**（>60 天） |  
| _S. viridans_ 等  | **36%**           | **13%**  | <5%               | **20%**       |  
| _Enterococcus_   | **11%**           | 5%       | 8%                | 13%           |  
| _S. aureus_      | **28%**           | **68%**  | **36%**           | **20%**       |  
| _S. epidermidis_ | **9%**            | <5%      | **17%**           | **20%**       |  
| GNB              | <5%               | <**5%**  | **6%**            | <5%           |  
| 其他               | <5%               | <5%      | 10%               | 10%           |  
| 真菌^              | 1%                | 1%       | 9%                | 3%            |  
| 培養陰性^^           | 11%               | <5%      | 17%               | 12%           |  
^ ↑風險因素包括糖尿病、留置導管、免疫抑制  
^^ 培養陰性可能包括：營養缺乏型鏈球菌、HACEK 群（Haemophilus para-influenzae 和 aphrophilus、Actinobacillus、Cardiobacterium、Eikenella 和 Kingella）、T. whipplei、Bartonella、Coxiella、Chlamydia、Legionella、Brucella（JAMA 2007;297:1354；Annals 2007;147:829；J Clin Microbiol 2012;50:216）  
  
## 臨床表現 (Lancet 2016;387:882)  
  
- 持續性菌血症 → 發燒 (80-90%)、寒戰、夜間盜汗、食欲不振、肌痛  
- 瓣膜或瓣膜周圍感染 → 心衰竭、傳導異常 (如房室傳導阻滯)  
- 敗血性栓塞：中風、栓塞性心肌梗塞、腎/脾/肺梗塞、感染性關節炎、骨髓炎  
- 免疫複合物現象：關節炎、腎小球腎炎  
- 亞急性心內膜炎可表現為亞急性進展的“B”症狀（疲倦、體重減輕）  
  
## 理學檢查  
  
- 心臟雜音 (85%)，新發心衰竭的症狀和徵兆（肺水腫、頸靜脈壓升高、水腫）  
- 皮膚/眼部變化（少見但高度特異性）  
- Janeway lesion（無痛性出血性斑塊，位於手掌/腳掌，因敗血性栓塞所致）  
- Osler node（因免疫複合物沉積引起的疼痛性指尖或趾尖結節）  
- 甲床出血線  
- Roth spot（視網膜出血）  
- 骨骼肌系統：脊柱壓痛，紅腫熱的關節  
- 神經學異常可能提示栓塞性中風；脊柱壓痛可能提示骨髓炎或硬膜外膿瘍  
- 植入裝置：評估中央靜脈導管（CVC）、節律器（PM）/植入型心臟整流去顫器（ICD）部位，及其他人工植入物的部位  
  
![[../attachments/9bfd16b74d174ac2dbd8b3c9fc4fcef1_MD5.jpeg|9bfd16b74d174ac2dbd8b3c9fc4fcef1_MD5]]  
  
## 診斷 (CID 2010;51:131; EHJ 2015;36:3075; Circ 2015;132:1435)  
  
- 血液培養（開始抗生素治療前）：從不同部位取3組（需氧瓶和厭氧瓶），間隔至少1小時。治療後，應至少進行兩次血液培養以確定清除情況，每24-48小時重複一次直到結果為陰性。  
- 連續心電圖以評估傳導疾病和 PR 間期延長（可能提示瓣膜周圍膿瘍）  
- 心臟超音波：所有患者進行經胸前心臟超音波（TTE）。如遇以下情況則需進行經食道心臟超音波（TEE）：  
	1. TTE 異常但無法診斷；  
	2. TTE 陰性但懷疑度高；  
	3. 懷疑或已有併發症（如房室傳導阻滯）；  
	4. 高風險患者（人工瓣膜、CIED、既往IE、先天性心臟病）；  
	5. _S. aureus_、_Enterococcus_ 或真菌感染；  
	6. 症狀和徵兆發生變化（如新發傳導異常、瓣膜返流等）；  
	7. 考慮縮短抗生素療程（10-14天）  
  
|                    | **敏感性** |         |         |  
| ------------------ | ------- | ------- | ------- |  
|                    | **NVE** | **PVE** | **膿腫**  |  
| **經胸前心臟超音波 (TTE)** | 39-58%  | 33%     | 18-63%  |  
| **經食道心臟超音波 (TEE)** | >90%    | 86%     | 76-100% |  
- 如 TTE/TEE 結果不明確或懷疑瓣膜周圍膿瘍，可進行EKG-gated cardiac CT  
- 如 TTE/TEE 結果不明確，FDG PET/CT 對懷疑人工瓣膜心內膜炎或⼼臟植入式電⼦裝置感染具有診斷價值  
- 如懷疑中樞神經系統擴散（感染性動脈瘤、栓塞性中風）或脊椎侵犯（脊椎骨髓炎、硬膜外膿瘍），應進行腦部/脊椎影像學檢查  
- 培養陰性心內膜炎：可能由於在進行血培養前使用了抗生素。PCR、細菌 16S 核糖體 RNA 和血清學可能有幫助。詳細病史詢問包括動物接觸、旅行、未經消毒的乳製品等。需要傳染病專科評估。考慮微生物學表格中的培養陰性病原體（如上所述）。  
  
### 修改後的杜克標準  
  
- **確診**：  
	- 2項主要標準  
	- 1項主要+3項次要  
	- 5項次要  
- **可能**：  
	- 1項主要+1項次要  
	- 3項次要  
  
| **主要標準**                                                                                                            | **次要標準**                                                                                                                                                      |     |  
| ------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------- | --- |  
| - 血液培養中出現常見心內膜炎病原體（在2套不同的培養中生長）<br>    <br>- _Coxiella_ 血清學≥1:800<br>    <br>- **心內膜受累**：植被、膿瘍、人工植入物脫落或**新發生的瓣膜逆流** | - 具有風險因子<br>    <br>- 發燒<br>    <br>- 血管現象：感染性動脈或肺栓塞、感染性動脈瘤、顱內出血、Janeway lesion<br>    <br>- 免疫現象：RF陽性、腎小球腎炎、Osler node、Roth spot<br>    <br>- 陽性血液培養但不符合主要標準 |     |  
敏感性約 90%，特異性 >95%，陰性預測值 ≥92% (CID 2000;30:633)  
  
## 治療（強烈建議進行感染科會診）  
  
| 病原體                                 | 治療（Circ 2015;132:1435）                                                                                                                                                                                              |  
| ----------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| 經驗性治療                               | NVE 或手術後超過12個月的 PVE： vancomycin + ceftriaxone<br><br>手術後12個月內的 PVE：vancomycin + ceftriaxone ± gentamicin（如腎功能良好）                                                                                                    |  
| _Strep_                             | Penicillin, ampicillin, ceftriaxone；如為 PVE，考慮與感染科討論是否加入gentamicin                                                                                                                                                   |  
| _Staph (S. aureus_ 和 _lugdunensis)_ | MRSA：vancomycin or daptomycin<br><br>MSSA：nafcillin, oxacillin, or cefazolin（如有中樞神經系統受累則避免使用，因為滲透性差）；vancomycin對 MSSA 的效果不如 β-lactam類<br><br>對於對 PCN 過敏的 MSSA，考慮脫敏療法<br><br>對於 PVE，考慮在感染科討論後使用rifampin / gentamicin |  
| _Enterococci_                       | Ampicillin + ceftriaxone或gentamicin；如為 VRE：linezolid, daptomycin, or ampicillin (if S)                                                                                                                              |  
| 革蘭氏陰性菌                              | HACEK：ceftriaxone, ampicillin or FQ。_Pseudomonas_：2 種抗Pseudomonas aeruginosa藥物 [例如，β-lactam類 +（aminoglycoside or FQ）]                                                                                               |  
| 真菌（念珠菌、麴菌）                          | _Candida_：amphotericin B ± flucytosine or micafungin<br><br>_Aspergillus_：amphotericin B or voriconazole<br><br>如有菌血症，需眼科會診以排除眼內炎                                                                                   |  
- 根據病原體分型和敏感性調整為針對性治療  
- 如正在使用抗凝劑或抗血小板藥物，通常可以繼續使用，除非有中風、顱內出血或需要緊急手術的顧慮  
- 持續監測心內膜炎的併發症（如心衰竭、傳導阻滯、骨髓炎、新發生的栓塞現象），這些情況即使在使用抗生素期間也可能發生  
- 治療通常持續 4-6 週  
- 在靜脈注射抗生素 **≥10 天** 後，如臨床合適且有可用的口服抗生素，可在與感染科會診後考慮改用口服藥物（NEJM 2019;380:415）  
- 無併發症的右側 NVE 或對 PCN 敏感的 _Streptococci_ → 2 週治療可能足夠  
- 靜脈注射藥物濫用（IVDU）相關的感染最好由包括成癮醫學在內的多學科團隊管理  
  
## 手術適應症（早期會診；JTCS 2017;153:1241；Circ 2021;143:e72）  
  
- 非常緊急手術：難治性心源性休克  
- 緊急手術（初次住院期間）：  
	- 有心衰竭症狀  
	- 穿透性感染：瓣環周圍膿瘍、心臟傳導阻滯、瘺管、傳導惡化  
	- 持續感染：在使用適當抗生素超過 5 天後血培養仍為陽性，贅生物增大或大贅生物  
	- 栓塞：反覆栓塞或伴有殘餘大（>10 mm）贅生物和嚴重的主動脈瓣逆流/二尖瓣逆流。腦栓塞並非禁忌症，除非有嚴重中風或出血（Stroke 2006;37:2094）  
	- _S. aureus_、真菌或多重抗藥性病原體感染  
	- PVE（如功能障礙或脫落則為非常緊急手術）  
  
## 心內膜炎預防 (Circ 2007;116:1736)  
  
| **心臟病變^** | **人工瓣膜；過去曾有心內膜炎；先天性心臟病**（包括未修復或不完全修復的發紺型先天性心臟病（姑息性分流或導管），使用人工材料完全修復的先天性心臟病後的前 6 個月；伴有瓣膜病變的心臟移植受者。（不再建議在後天瓣膜功能不全、二尖瓣脫垂伴瓣葉增厚或返流、肥厚型心肌病中進行預防。）                                        |  
| --------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| **手術^**   | **牙科：**涉及牙齦組織或牙齒根尖區域的操作或穿透口腔黏膜（例如，拔牙、牙周手術、植牙、根管治療、洗牙）                                                                                                                              |  
| **預防方案**  | 口服：amoxicillin 2 g，手術前 30-60 分鐘<br><br>無法口服者：ampicillin 2 g IM/IV 或 cefazolin or ceftriaxone 1 g IM/IV<br><br>對 PCN 過敏者：cephalexin or azithromycin or clarithomycin or doxycycline |  
^患者應同時符合兩個適應症（高風險病變和高風險手術）才能進行預防  
  
# BACTEREMIA  
  
## Definitions  
  
- Primary bacteremia: bloodstream infection due to direct inoculation of the blood  
- Central line associated bloodstream infection (CLABSI): bacteremia in which the same organism is growing from peripheral and catheter cultures (CID 2009;49:1)  
- Secondary bacteremia: infection of another site (eg, UTI, pneumonia, colitis, etc.) spreading to blood  
- Contaminant: bacteria growing in a blood culture that does not represent a true infection  
  
## Risk factors for bloodstream infections (JAMA 2012;308:502; CID;2020;71)  
  
- Syndromes with high likelihood of bacteremia:  
	- Sepsis  
	- Endovascular infections: endocarditis, infection of pacemaker, vascular graft or IV catheter  
	- Vertebral osteomyelitis, epidural abscess, septic arthritis  
- Risk factors: indwelling lines, IVDU, immunosupp. (neutropenic, transplant)  
- Organisms  
	- More likely pathogenic: *S. aureus*, β-hemolytic strep, enterococci, GNR, *S. pneumo*, *Neisseria*, *Candida*  
	- Less likely pathogenic: coag-neg staph, diphtheroids, Cutibacterium  
- Time to growth: <24 h → higher risk, >72 h → lower risk (except slow-growing, eg, HACEK)  
- Factors increasing likelihood of endocarditis: high-grade bacteremia w/o source, persisting after line removal or drainage of focal source, in hosts at risk for endocarditis or w/ organisms known to cause IE; emboli  
  
## Diagnosis  
  
- ≥2 sets blood culture prior to antibiotics (set = aerobic + aneaerobic culture) at separate puncture sites  
- If proven bacteremia, daily surveillance cultures until **48 hrs of ⊖ cultures**. May not need for GNRs (ClD 2017;65:1776)  
- Transthoracic echocardiography (TTE)/transesophageal echocardiography (TEE) if concern for endocarditis (see IE section)  
- **TTE** and **urgent ophthalmology** evaluation if yeast is growing in blood culture  
  
## Treatment (CID 2009;49:1; JAMA 2020;323:2160)  
  
- Empiric antibiotics based on Gram stain, culture, & clinical syndrome, then tailor based on sensitivity  
  
### Short-Term Central Venous Catheter-Related Bloodstream Infections  
  
| Pathogen                   | Management                                                                                                                                                                                                                                                                                                                                                                                                          |  
| -------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| **_S. aureus_**            | Risk of endocarditis in bacteremia: ˜25% (_JACC_ 1997;30:1072)<br><br>ID consult a/w ↓ mortality (_ClD_ 2015;60:1451)<br><br>Remove CVC, evaluate for endocarditis, osteo, hardware infections<br><br>Preferred antibiotics: MSSA → nafcillin, oxacillin, or cefazolin. MRSA → vancomycin. Duration: 2 wks if normal host, no implants, no evidence of endocarditis or metastatic complications. Otherwise 4-6 wks. |  
| **Coag-neg staphylococci** | CVC retention does not ↓ rate of resolution, but a/w ↑ rate of recurrence (_CID_ 2009;49:1187). If CVC left, treat 10-14 days; if removed 5-7 days.                                                                                                                                                                                                                                                                 |  
| **_Enterococcus_**         | Remove CVC & treat for 7-14 days                                                                                                                                                                                                                                                                                                                                                                                    |  
| GNR**                      | Remove CVC esp if _Pseudomonas._ Therapy for 14 days (7 if uncomplicated).                                                                                                                                                                                                                                                                                                                                          |  
| **Yeast**                  | Remove CVC & treat for 14 from first ⊖ BCx. ID consult a/w ↓ mortality.                                                                                                                                                                                                                                                                                                                                             |  
- Persistently ⊕ BCx: remove CVCs, look for metastatic infection (endocarditis, septic arthritis, osteo), infected thrombosis, or prosthetic material (vascular graft, PPM)  
  
# BACTERIAL ENDOCARDITIS  
  
## Definition  
  
- Infection of endothelium of heart (including but not limited to the valves) including both prosthetic valve endocarditis (PVE) and native valve endocarditis (NVE)  
  
## Risk Factors  
- Abnormal valve (JAMA 1997;277:1794; JACC 2018;72:2443)  
	- High risk: prior endocarditis, prosthetic valve or ring, some congenital heart disease (unrepaired cyanotic; shunt/conduit; prosthesis in past 6 mos), transplant heart, valvulopathy, ventricular assist device  
	- Medium risk: previous rheumatic fever, non-rheumatic valve disease (including MVP w/ MR or thickened leaflet), HCM, bicuspid AoV  
- Risk of bacteremia: IVDU, indwelling venous catheters, hemodialysis, prosthetic material in heart (eg, pacemaker, ICD, graft), poor dentition  
  
## Microbiology of Endocarditis  
  
|                      | **Native Valve (NVE)** |          | **Prosthetic Valve (PVE)** |                  |  
| -------------------- | ---------------------- | -------- | -------------------------- | ---------------- |  
| **Etiology**         | **Non-IVDA**           | **IVDU** | **Early** (≤60 days)       | **Late** (>60 d) |  
| _S. viridans_ et al. | **36%**                | **13%**  | <5%                        | **20%**          |  
| _Enterococcus_       | **11%**                | 5%       | 8%                         | 13%              |  
| _S. aureus_          | **28%**                | **68%**  | **36%**                    | **20%**          |  
| _S. epidermidis_     | **9%**                 | <5%      | **17%**                    | **20%**          |  
| GNR                  | <5%                    | <**5**%  | **6%**                     | <5%              |  
| Other                | <5%                    | <5%      | 10%                        | 10%              |  
| Fungal^              | 1%                     | 1%       | 9%                         | 3%               |  
| Culture ⊖^^          | 11%                    | <5%      | 17%                        | 12%              |  
^ ↑ risk w/DM, indwelling lines, immunosupp.  
^^ Cx ⊖ = abiotrophic strep, HACEK (Haemophilus para-influenzae & aphrophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella), T. whipplei, Bartonella, Coxiella, Chlamydia, Legionella, Brucella (JAMA 2007;297:1354; Annals 2007;147:829; J Clin Microbiol 2012;50:216)  
  
## Clinical manifestation (Lancet 2016;387:882)  
  
- Persistent bacteremia → fever (80-90%), rigors, night sweats, anorexia, myalgias  
- Valvular or perivalvular infection → HF, conduction abnormalities (eg, AVB)  
- Septic emboli: stroke, embolic MI, renal/splenic/pulmonary infarcts, septic arthritis, osteo  
- Immune complex phenomena: arthritis, glomerulonephritis  
- Subacute endocarditis can present with subacute progressive “B” sx (fatigue, wt loss)  
  
## Physical exam  
  
- Cardiac murmur (85%), s/s of new HF (pulmonary edema, JVP elevation, edema)  
- Skin/ocular changes (uncommon but highly specific)  
- Janeway lesions (painless hemorrhagic macules on palms/ soles due to septic emboli)  
- Osler's nodes (painful nodules on pads of digits due to immune complex deposition)  
- Splinter hemorrhages in fingernails or toenails  
- Roth spots (retinal hemorrhages)  
- MSK: point tenderness along spine, red/hot joints  
- Neurologic deficits c/f embolic stroke; vertebral tenderness c/f osteo or epidural abscess  
- Devices: evaluate CVCs, PM/ICD pocket, and sites of other hardware/ prosthetics  
  
![[../attachments/9bfd16b74d174ac2dbd8b3c9fc4fcef1_MD5.jpeg|9bfd16b74d174ac2dbd8b3c9fc4fcef1_MD5]]  
  
## Diagnosis (CID 2010;51:131; EHJ 2015;36:3075; Circ 2015;132:1435)  
  
- Blood cultures (before abx): 3 sets (aerobic & anaerobic bottles) from different sites, ideally spaced ≥1 h apart. ✓ BCx (at least 2 sets) after appropriate abx have been initiated to document clearance; repeat q24-48h until ⊖.  
- Serial ECGs to assess for conduction disease and ↑ PR interval (c/f perivalvular abscess)  
- Echocardiogram: TTE in all Pts. TEE if (i) TTE abnl but nondx, (ii) TTE ⊖ but high suspicion, (iii) complications suspected or present (eg, AVB), (iv) high-risk (prosthetic valve, CIED, prior IE, congenital heart dis.), (v) S. aureus, enterococcus, or fungus, (vi) Δ in signs or sx (eg, new conduction abnl, regurgitation, etc.) (vii) if considering a shortened course (10-14 d) of abx (vide infra)  
  
|                           | **Sensitivity** |         |             |  
| ------------------------- | --------------- | ------- | ----------- |  
|                           | **NVE**         | **PVE** | **Abscess** |  
| **Transthoracic (TTE)**   | 39-58%          | 33%     | 18-63%      |  
| **Transesophageal (TEE)** | >90%            | 86%     | 76-100%     |  
  
- Gated cardiac CT useful if TTE/TEE equivocal or suspected paravalvular abscess  
- PET/CT using FDG useful for suspected PVE or CIED infxn if TTE/TEE equivocal  
- Brain/spine imaging if concern for CNS spread (mycotic aneurysms, embolic stroke) or spinal involvement (vertebral osteo, epidural abscess)  
- Cx ⊖ endocarditis: may be due to abx prior to BCx. PCR, bacterial 16S ribosomal RNA, serol. may be helpful. Detailed hx: animal exposure, travel, unpast. dairy, etc. ID eval. Consider organisms listed in Cx ⊖ footnote in microbiology table (vide supra).  
  
### Modified Duke Criteria  
  
- **Definitive**: 2 major _or_ 1 major+3 minor _or_ 5 minor; **Possible**: 1 major+1 minor _or_ 3 minor  
  
| **Major**                                                                                                                                                                                                                                       | **Minor**                                                                                                                                                                                                                                                                                               |  
| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| - Blood cultures with common endocarditis pathogen (grown in 2 separate culture)<br>    <br>- _Coxiella_ serology ≥1:800<br>    <br>- **Endocardial involvement**: vegetation, abscess, prosthetic dehiscence or **new valvular regurgitation** | - Predisposing condition (see risk factors)<br>    <br>- Fever<br>    <br>- Vascular phenomena: septic arterial or pulmonary emboli, mycotic aneurysms, ICH, Janeway lesions<br>    <br>- Immune phenomena: ⊕ RF, GN, Osler's nodes, Roth spots<br>    <br>- ⊕ blood culture not meeting major criteria |  
Se ˜90%, Sp >95%, NPV ≥92% (CID 2000;30:633).  
  
## Treatment (ID consult is strongly recommended)  
  
| Pathogen                              | Treatment (Circ 2015;132:1435)                                                                                                                                                                                                                                                                 |  
| ------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| Empiric                               | NVE or PVE >12 mos post-op: vancomycin + ceftriaxone<br><br>PVE <12 mos post op: vancomycin + ceftriaxone ± gentamicin (if OK renal function)                                                                                                                                                  |  
| _Strep_                               | Penicillin, ampicillin, ceftriaxone; if PVE consider gentamicin in discussion w/ ID                                                                                                                                                                                                            |  
| _Staph (S. aureus_ and _lugdunensis)_ | MRSA: vancomycin or daptomycin<br><br>MSSA: nafcillin, oxacillin, or cefazolin (avoid if CNS involvement due to poor penetration); vanc inferior to β-lactam for MSSA<br><br>For PCN allergy w/ MSSA consider desensitization<br><br>Consider rifampin / gentamicin in PVE in discussion w/ ID |  
| _Enterococci_                         | Ampicillin + CTX or gent]; if VRE: linezolid, dapto, ampicillin if sensitive                                                                                                                                                                                                                   |  
| Gram negatives                        | HACEK: CTX, ampicillin or FQ. _Pseudomonas_: 2 anti-Pseudomonal agents [eg, β-lactam + (aminoglycoside or FQ)]                                                                                                                                                                                 |  
| Fungi (candida, aspergillus)          | _Candida_: amphotericin B ± flucytosine or micafungin<br><br>_Aspergillus_: amphotericin B or voriconazole<br><br>Ophtho consult for fungemia to rule out endophthalmitis                                                                                                                      |  
- De-escalate abx to organism-directed therapy based on speciation and sensitivities  
- If on anticoagulation or antiplatelet, typically can continue unless concern for stroke, intracranial hemorrhage, or need for emergent surgery  
- Monitor for complications of endocarditis (CHF, conduction block, osteomyelitis, new embolic phenomenon) which can occur even on abx  
- Duration is usually 4-6 wks  
- After ==**≥10d**== IV abx can consider Δ'ing to PO if clinically appropriate and available PO abx in consultation with ID (NEJM 2019;380:415)  
- Uncomplicated right-sided NVE or PCN-S Strep spp → 2 wks may be adequate  
- IVDU-associated best managed by multidisciplinary teams including Addiction Medicine  
  
## Indications for surgery (consult early; JTCS 2017;153:1241; Circ 2021;143:e72)  
  
- Emergent if refractory cardiogenic shock  
- Urgent (during initial hospitalization):  
	- Sx HF  
	- Penetrating infection: periannular abscess, heart block, fistula, worsening conduction  
	- Persistent infection: ⊕ BCx after >5 d of appropriate abx, ↑ or ? large vegetation  
	- Emboli: recurrent or w/ residual large (>10 mm) vegetation & severe AR/MR. Cerebral emboli not contraindic. unless severe stroke or hemorrhage (Stroke 2006;37:2094).  
	- S. aureus, fungal or multiRx-resistant organisms  
	- PVE (emergent if dysfunction or dehiscence)  
  
## Endocarditis Prophylaxis (Circ 2007;116:1736)  
  
| **Cardiac conditions^** | **Prosthetic valve; previous endocarditis; congenital heart disease** (CHD) including unrepaired or incompletely repaired cyanotic CHD (palliative shunts or conduits), 1st 6 mo after completely repaired CHD using prosthetic material; cardiac transplant recipients w/ valvulopathy. (Prophylaxis no longer rec. in acquired valvular dysfxn, bicuspid AoV, MVP with leaflet thickening or regurgitation, HCM.) |  
| ----------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| **Procedures^**         | **Dental:** manipulation of gingival tissue or periapical region of teeth or perf oral mucosa (eg, extraction, periodontal, implant, root canal, cleaning)                                                                                                                                                                                                                                                          |  
| **Regimens**            | Oral: amoxicillin 2 g 30-60 min before<br><br>Unable to take PO: amp 2 g IM/IV or cefazolin or ceftriaxone 1 g IM/IV<br><br>PCN-allergic: cephalexin or azithro or claritho or doxy                                                                                                                                                                                                                                 |  
^Pts should meet both indications (high-risk condition & high-risk procedure) to qualify for prophylaxis  
  
# 考古題  
## 專師  
  
  
## 內科醫師  
  
  
